Second Sight Medical Products (NASDAQ:EYES) will release its earnings data after the market closes on Tuesday, August 6th. Analysts expect Second Sight Medical Products to post earnings of ($0.06) per share for the quarter.
Second Sight Medical Products (NASDAQ:EYES) last posted its quarterly earnings results on Wednesday, May 15th. The medical device company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.04). Second Sight Medical Products had a negative return on equity of 326.46% and a negative net margin of 497.18%. The business had revenue of $1.13 million for the quarter, compared to analysts’ expectations of $1.70 million. On average, analysts expect Second Sight Medical Products to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of Second Sight Medical Products stock opened at $0.77 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.71 and a quick ratio of 4.50. Second Sight Medical Products has a 52-week low of $0.63 and a 52-week high of $1.98. The company has a market capitalization of $99.50 million, a PE ratio of -1.47 and a beta of 2.27. The business has a 50 day moving average price of $0.80.
Several research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Second Sight Medical Products from a “sell” rating to a “hold” rating in a report on Monday, June 17th. ValuEngine cut shares of Second Sight Medical Products from a “hold” rating to a “sell” rating in a report on Tuesday, May 14th.
Second Sight Medical Products Company Profile
Second Sight Medical Products, Inc develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury.
Further Reading: Why is momentum important to successful trading?
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.